Intravenous Immunoglobulin Treatment Patterns and Outcomes in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A US Claims Database Analysis
Open Access
- 12 May 2023
- journal article
- research article
- Published by Springer Nature in Neurology and Therapy
- Vol. 12 (4) , 1119-1132
Abstract
Introduction Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare progressive or relapsing inflammatory disease. Intravenous immunoglobulin (IVIG) is recommended as a first-line therapy. The aim of this study was to describe real-world treatment patterns and outcomes of patients with CIDP in the Define initiating IVIG treatment. Methods This cohort study used health insurance claims data from the Merative MarketScan Research Databases (2008–2018). Adult patients (≥ 18 years old) with CIDP without prior immunoglobulin treatment were identified using International Statistical Classification of Diseases and Related Health Problems (ICD) codes, and patients subsequently initiating IVIG were included in the analysis. Real-world IVIG treatment patterns and treatment and safety outcomes (assessed via ICD codes) were described. Results In total, 3975 patients (median age 58 years) with CIDP who initiated IVIG were identified. After the initial IVIG loading period, patients received IVIG at a median dosing interval of 21 days (quartile [Q]1, Q3: 7, 28), and continued treatment for a median of 129 days (Q1, Q3: 85, 271). After the 2-year follow-up period, 55% of patients had discontinued all IVIG treatment; more than one-half of these discontinuations occurred within 4 months. Diagnoses of impaired functional status were evident in more than 30% of patients at baseline, but at lower rates during follow-up. Rates of new-onset safety outcomes after IVIG treatment were low. Conclusion This real-world analysis of IVIG treatment patterns and treatment and safety outcomes of patients with CIDP who initiated IVIG highlights the unmet need for improved long-term management. Further research is needed to evaluate the use of functional status measures as endpoints for immunoglobulin treatment effectiveness.Keywords
Funding Information
- Takeda Development Center Americas, Inc.
This publication has 35 references indexed in Scilit:
- An update on the management of chronic inflammatory demyelinating polyneuropathyTherapeutic Advances in Neurological Disorders, 2012
- Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010Transfusion, 2012
- Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathyJournal of Neurology, Neurosurgery & Psychiatry, 2010
- A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathyJournal of the Peripheral Nervous System, 2010
- European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society — First RevisionEuropean Journal of Neurology, 2010
- Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single‐blinded cross‐over trialEuropean Journal of Neurology, 2009
- Disability and health status in patients with chronic inflammatory demyelinating polyneuropathyDisability and Rehabilitation, 2009
- Fatigue as the main presenting symptom of chronic inflammatory demyelinating polyradiculoneuropathy: a study of 11 casesJournal of the Peripheral Nervous System, 2005
- Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy2002
- Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathyAnnals of Neurology, 2001